-
May 4, 2023 Palobiofarma announces a collaboration with the Foundation for Prader Willi Research (FPWR) for the development of PBF-999 as a novel treatment for the Prader Willi Research syndrome.
Read more: May 4, 2023 Palobiofarma announces a collaboration with the Foundation for Prader Willi Research (FPWR) for the development of PBF-999 as a novel treatment for the Prader Willi Research syndrome.[May 4, 2023] – [Pamplona, Navarra] – The Foundation for Prader Willi Research (FPWR) has provided a new venture philanthropy award, in the form of a convertible loan, to Palobiofarma S.L., a Spanish biopharmaceutical company focused on developing innovative treatments…
-
December 16th. 2021. Palobiofarma announces that it has been included among the 99 innovative companies in the European Innovation Council Accelerator.
Read more: December 16th. 2021. Palobiofarma announces that it has been included among the 99 innovative companies in the European Innovation Council Accelerator.Palobiofarma has received the approval of the European project that finances Phase II of the PBF-680 product in COPD. Additionally, it offers the possibility of partial financing of Phase III of PBF-680. This is an important financing in a very…
-
November 10th. 2021. Palobiofarma announces positive results in the Phase IIa clinical trial evaluating it´s first in class investigational treatment PBF-677 in patients with mild to moderate ulcerative colitis.
Read more: November 10th. 2021. Palobiofarma announces positive results in the Phase IIa clinical trial evaluating it´s first in class investigational treatment PBF-677 in patients with mild to moderate ulcerative colitis.The Phase II trial studied the safety, tolerability, and preliminary efficacy of PBF-677 in patients with mild to moderate Ulcerative Colitis in flair condition on top of the standard of care Mesalazine (5-ASA). 32 patients were recruited in the trial,…
-
September 09. 2021. Palobiofarma announces the finalization of the Phase IIa clinical trial of it´s first in class investigational treatment PBF-677 in patients with mild to moderate ulcerative colitis
Read more: September 09. 2021. Palobiofarma announces the finalization of the Phase IIa clinical trial of it´s first in class investigational treatment PBF-677 in patients with mild to moderate ulcerative colitisThe Phase II trial studies the safety, tolerability and preliminary efficacy of PBF-677 in patients with mild to moderate Ulcerative Colitis in flair condition on top of the standard of care (5-ASA). 30 patients were recruited in the trial, 20…
-
Positive clinical results of Palobiofarma´s adenosine A1 antagonist PBF-680 presented at the European Respiratory Society meeting.
Read more: Positive clinical results of Palobiofarma´s adenosine A1 antagonist PBF-680 presented at the European Respiratory Society meeting.The results of an allergen POC trial in asthmatics will summarized by Dr. David Ramos, principal investigator of the PBF-680 clinical program, in an oral presentation titled: PBF-680, an oral A1 adenosine receptor antagonist, inhibits the late allergic response (LAR)…
-
Palobiofarma announces positive results from the Phase II clinical trial evaluating the preliminary efficacy and safety of its adenosine A1 receptor antagonist PBF-680 in mild to moderate asthmatics patients.
Read more: Palobiofarma announces positive results from the Phase II clinical trial evaluating the preliminary efficacy and safety of its adenosine A1 receptor antagonist PBF-680 in mild to moderate asthmatics patients.The results confirm a clinically and statistically significant improvement in trough FEV1 of asthmatic patients taking 10mg of PBF-680 for 14 days compared to placebo. Additionally, patients administered with PBF-680 showed statistically significant improvement compared to placebo treated patients in…
-
June 8th, 2020: Palobiofarma joins the fight against the Covid-19 pandemia
Read more: June 8th, 2020: Palobiofarma joins the fight against the Covid-19 pandemiaThe company announced the initiation a of a drug discovery program towards the identification of novel oral drugs specifically designed to treat infections caused by Corona viruses. Recent scientific publications have identified the protein ACE2 (angiotensin converting enzyme 2) as…
-
XOMA and Inveready Acquires Royalty Interest Position in Six Clinical-Stage Assets from Palobiofarma
Read more: XOMA and Inveready Acquires Royalty Interest Position in Six Clinical-Stage Assets from PalobiofarmaIncludes royalty interest in NIR178 September 30 2019 XOMA Corporation (NASDAQ: XOMA), announced today it has acquired a royalty interest in six clinical-stage assets targeting the adenosine pathway for $10.0 million from Palobiofarma S.L. One of the assets, NIR178, is…
-
Palobiofarma has started the clinical development of PBF-1650
Read more: Palobiofarma has started the clinical development of PBF-1650Palobiofarma has started the clinical development of PBF-1650, a novel treatment of autoimmune diseases, like NASH and psoriasis. The “first in human” study will take place at the University Clinic of Navarre (CUN). PBF-1650 will be the program number six…
-
Palobiofarma completed the dose escalation part of the Phase I study with PBF-999 in cancer patients
Read more: Palobiofarma completed the dose escalation part of the Phase I study with PBF-999 in cancer patientsPalobiofarma has completed the dose escalation of the Phase I clinical trial evaluating the safety and tolerability of the novel PDE10/A2a dual antagonist PBF-999 in patients with solid tumors. The trial has been conducted at the Vall D Hebron Hospital,…
